Novartis, already up on CRISPR, CAR-T, looks to new gene editing R&D – FierceBiotech
FierceBiotech |
Novartis, already up on CRISPR, CAR-T, looks to new gene editing R&D
FierceBiotech This tech builds on the work Novartis is doing out of its phoenix-from-the-flames cell and gene therapy unit, which includes CAR-T and collaborative work on CRISPR-Cas9. In late August, Novartis became the first-ever company to gain approval for a … |
